NCT06732336View on ClinicalTrials.gov

HER2-PET Imaging in HER2-low Breast Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Breast Cancer Metastatic
Interventions
DIAGNOSTIC_TEST

89Zr-trastuzumab

Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.

Trial Locations (1)

J1H5N4

RECRUITING

Centre de recherche du CHUS, Sherbrooke

All Listed Sponsors
collaborator

Université de Sherbrooke

OTHER

lead

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

OTHER